Session » SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 2083

A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy

1:00PM-3:00PM: Abstract Number: 2082

A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy

1:00PM-3:00PM: Abstract Number: 2088

Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort

1:00PM-3:00PM: Abstract Number: 2068

All-Cause Mortality in a Systemic Lupus Erythematosus Cohort

1:00PM-3:00PM: Abstract Number: 2098

Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study

1:00PM-3:00PM: Abstract Number: 2059

Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry

1:00PM-3:00PM: Abstract Number: 2097

Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 2103

Association of Telomere Length with Phenotypic Frailty in Adults with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2091

Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network

1:00PM-3:00PM: Abstract Number: 2105

Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2081

COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave

1:00PM-3:00PM: Abstract Number: 2084

COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2053

Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review

1:00PM-3:00PM: Abstract Number: 2106

Disparities of African American Mortality Trends in South Carolina Lupus Cohort

1:00PM-3:00PM: Abstract Number: 2077

Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?

1:00PM-3:00PM: Abstract Number: 2102

Does Remission According Definition of Remission in SLE (DORIS) 2021 Match the Treating Rheumatologist Judgment? Analysis at Recruitment of a Prospective Study of 500 SLE Patients from a Spanish Multicenter Cohort

1:00PM-3:00PM: Abstract Number: 2099

Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers

1:00PM-3:00PM: Abstract Number: 2085

Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study

1:00PM-3:00PM: Abstract Number: 2100

Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2080

Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample

1:00PM-3:00PM: Abstract Number: 2072

Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index

1:00PM-3:00PM: Abstract Number: 2090

Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)

1:00PM-3:00PM: Abstract Number: 2058

Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2092

Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE

1:00PM-3:00PM: Abstract Number: 2093

Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort

1:00PM-3:00PM: Abstract Number: 2070

Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis

1:00PM-3:00PM: Abstract Number: 2061

Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 2060

Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1

1:00PM-3:00PM: Abstract Number: 2056

Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis

1:00PM-3:00PM: Abstract Number: 2066

Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population

1:00PM-3:00PM: Abstract Number: 2063

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus

1:00PM-3:00PM: Abstract Number: 2078

Mesangial Lupus Nephritis: Long Term Outcomes

1:00PM-3:00PM: Abstract Number: 2101

Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study

1:00PM-3:00PM: Abstract Number: 2057

Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)

1:00PM-3:00PM: Abstract Number: 2074

Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study

1:00PM-3:00PM: Abstract Number: 2062

Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US

1:00PM-3:00PM: Abstract Number: 2094

Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)

1:00PM-3:00PM: Abstract Number: 2067

Predictors of Organ Damage Accrual by Domains

1:00PM-3:00PM: Abstract Number: 2107

Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension

1:00PM-3:00PM: Abstract Number: 2087

Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty

1:00PM-3:00PM: Abstract Number: 2086

Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2069

Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort

1:00PM-3:00PM: Abstract Number: 2075

Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids

1:00PM-3:00PM: Abstract Number: 2096

Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2055

SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?

1:00PM-3:00PM: Abstract Number: 2079

Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2065

Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares

1:00PM-3:00PM: Abstract Number: 2089

The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients

1:00PM-3:00PM: Abstract Number: 2073

The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies

1:00PM-3:00PM: Abstract Number: 2071

The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase

1:00PM-3:00PM: Abstract Number: 2104

The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE

1:00PM-3:00PM: Abstract Number: 2054

Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process

1:00PM-3:00PM: Abstract Number: 2064

Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE

1:00PM-3:00PM: Abstract Number: 2076

Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 2052

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population

1:00PM-3:00PM: Abstract Number: 2095

Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].